Shearman Mark S 4
4 · Editas Medicine, Inc. · Filed Feb 15, 2023
Insider Transaction Report
Form 4
Shearman Mark S
EVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-02-13$9.67/sh−2,790$26,966→ 65,559 total
Footnotes (1)
- [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 10, 2023. The sale does not represent a discretionary trade by the Reporting Person.